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OBJECTIVES: There is a growing number of patients on the waiting list for liver 
transplantation, which is currently the only treatment option for patients with 
severe hepatic cirrhosis. The aim of this study was to determine the main factors 
and the impact of the cost of maintaining the cirrhotic patients on the waiting list 
for liver transplant. METHODS: We evaluated 493 patients on the waiting list for 
liver transplantation between the years 2012 and 2014. Of these 139 were called 
to transplantation, 190 remained on the waiting list, 106 were removed by health 
status and 58 died in the list. We used a detailed analysis of micro-costs on the 
waiting list, including clinical data and the cost of materials, drugs, laboratorial 
tests, human resources and hospitalizations. RESULTS: The total cost for patients 
with MELD> 30 was US$10,003.31 ± 7,277.82, MELD 15-29 US$6,585.66 ± 7,526.33 and 
MELD< 15 US$3,201.98 ± 5,001.30 (p < 0.001). The time spent in waiting list was 211 
± 228 days to MELD> 30, 308.17 ± 285.58 to MELD 15-30 and 209.1 ± 208.23 days to 
MELD< 15 (p< 0.001). Hospitalizations occurred in 69.9% of patients with MELD> 30, 
56.4% in MELD 15-30 and 25.8% in MELD< 15 (p< 0.05). The cost of hospitalizations 
was US$9,836.15 ± 7,024.82 in patients with MELD> 30, US$7,442.51 ± 7,792.56 for 
patients with MELD 15-30 and US$6,470.01 ± 6,927.64 to MELD< 15 (p< 0.05), cor-
responding to 68.1%, 60.9% and 51.1% of total expenditures respectively. The cost 
of medications and laboratorial tests for patients with MELD> 30 was US$3,826.31 
± 3,649.99, US$2,480.15 ± 2,996.56 to MELD 15-30 and US$1,271.28 ± 1,987.91 to 
MELD< 15 (p< 0.001). CONCLUSIONS: More severe patients have high-cost on wait-
ing list for liver transplantation. The long time on waiting list, complications that 
lead to hospitalizations, and expensive laboratorial tests and medications cause a 
great financial impact on the public health system.
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OBJECTIVES: New Hepatitis C (HCV) therapies are more effective at treating HCV, 
but come at higher financial costs. Boceprevir has been used with peginterferon 
and ribavirin antivirals for treatment of HCV, achieving sustained virologic response 
(SVR) rates of 65% in clinical trials. Simeprevir, sofosbuvir and combination ledipas-
vir and sofosbuvir are new therapies that have achieved SVR of over 90% in phase III 
clinical trials. Estimating the cost effectiveness of these new therapies is important 
for providers to determine which treatments to adopt in the context of growing cost 
concerns. METHODS: We used Markov simulation to evaluate the cost effectiveness 
of simeprevir, sofosbuvir and combination therapy ledipasvir and sofosbuvir vs. 
the assumed standard of care, boceprevir, among HCV genotype 1 patients over a 
30-year time horizon. Patients progress through stages of the natural history of HCV-
liver fibrosis/cirrhosis, liver transplant and death. Costs, QALYs and outcomes were 
estimated from clinical trials and previously published literature. We calculated 
the incremental net monetary benefit (INMB) between each therapy and standard 
of care. We ran multivariate probabilistic sensitivity analyses (PSA) to quantify the 
uncertainty of the results. RESULTS: New therapies have higher costs and yield 
higher QALYs than boceprevir. Simeprevir at 12 and 24 weeks have the highest INMB 
($85,335.02 and $19,069.64, respectively). Sofosbuvir/ribavirin has a net monetary 
loss compared to the standard of care. The results identify the simeprevir therapy 
to be the most cost effective. PSA reveals simeprevir has the highest likelihood of 
being cost-effective as compared to boceprevir when all inputs are varied simulta-
neously. CONCLUSIONS: Of the new HCV therapies, simeprevir therapy is the best 
value for money when compared to boceprevir. Simeprevir yields the highest QALYs 
of the newer therapy regimens. Further research should focus on patient adherence 
to therapy and associative costs of adverse events to better elucidate value.
PGI18
a cosT-uTIlITy analysIs of bIoloGIcs for moderaTe-To-severe 
crohn’s dIsease: evIdence synThesIs usInG a bayesIan neTwork  
meTa-analysIs
Bounthavong M.1, Bae Y.H.2, Devine B.3, Veenstra D.L.3
1Univer, Seattle, WA, USA, 2Western University of Health Sciences, Pomona, CA, USA, 3University 
of Washington, Seattle, WA, USA
OBJECTIVES: To evaluate the cost-effectiveness of infliximab, adalimumab, certoli-
zumab pegol, and vedolizumab in Moderate-to-Severe Crohn’s disease from a US 
payer perspective with evidence synthesis from a Bayesian network meta-analysis 
(NMA). METHODS: A Markov model was constructed to evaluate the lifetime cost-
effectiveness of biologics and active control (azathioprine) in Crohn’s disease. The 
model used a 3-month cycle with six health states: Moderate-to-Severe, Mild-to-
Severe, Remission, Severe/Fulminant, Post-Surgery, and Death. Transition probabilities 
from Moderate-to-Severe to Remission were synthesized using a Bayesian NMA. Other 
transition probabilities and utility values were derived from the literature. Drug costs 
were based on Medicare Part-B Drug and Biological Average Sales Price Payment files. 
Costs and QALYs were discounted at 3-percent/year. One-way and probabilistic sensi-
tivity analyses (PSA) tested the robustness of the results. Willingness-to-pay threshold 
of $100,000/QALY was considered cost-effective. RESULTS: Transition probabilities 
(Moderate-to-Severe to Remission states) for active control, infliximab, adalimumab, 
certolizumab pegol, and vedolizumab were 0.240, 0.392, 0.483, 0.422, and 0.426, respec-
tively. Utility gained for active control, infliximab, adalimumab, certolizumab pegol, 
and vedolizumab were 17.84, 26.32, 26.35, 26.33, and 26.33 QALYs, respectively. Total 
direct costs for active control, infliximab, adalimumab, certolizumab pegol and vedoli-
zumab were $289,300, $330,700, $425,900, $547,800, and $423,200, respectively. ICER for 
infliximab compared to active control was $4,881/QALY gained. ICER for adalimumab 
GasTroInTesTInal dIsorders – cost studies
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OBJECTIVES: Rifaximin is a minimally absorbed antimicrobial agent that has demon-
strated efficacy for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in 
3 multicenter, randomized, controlled trials. After an initial 2-week course of therapy, 
rifaximin should be considered for repeat treatment only upon recurrence of symp-
toms, in contrast to other IBS treatment options that require chronic administration 
to maintain symptom improvement. The aim of this study was to evaluate the cost of 
adopting rifaximin for treating patients with IBS-D. METHODS: A model was created 
to project the incremental budget impact of adding rifaximin for treating patients 
with IBS-D in the US. The budget impact (2014 dollars) with rifaximin was estimated 
based on a hypothetical health plan with 10,000,000 members and 138,813 treated IBS 
patients receiving antidiarrheals, rifaximin, antispasmodics, alosetron, lubiprostone, 
linaclotide, and tricyclic antidepressants. Drug acquisition and office visit costs were 
applied to estimate the budget impact relative to the current environment over 3 years. 
Uptake of rifaximin was assumed to be 3.5% (year 1), 8.5% (year 2), and 15% (year 3). 
Adverse events and their associated costs were deemed similar between treatments 
and not included. RESULTS: The projected 1-, 2-, and 3-year budget impact of rifaximin 
resulted in annual savings for the health plan of $4,673,829 [per member per month 
(PMPM): $0.04], $11,350,728 (PMPM: $0.09), and $20,030,696 (PMPM: $0.17), totaling 
$36,055,253 over 3 years. Model results were most sensitive to time horizon, unit drug 
costs, and annual doses of alosetron and rifaximin; however, these only impacted the 
magnitude of savings relative to the current environment. Savings were expected when 
rifaximin was administered for up to 2 courses of therapy annually. CONCLUSIONS: 
This model suggests that the treatment of IBS-D with rifaximin, despite its higher unit 
cost, may be associated with savings when used up to twice per year.
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OBJECTIVES: The purpose of this study is to estimate the annual budget impact 
and the cost Per Member per Month of the testing and treatment of hepatitis C in 
the Medi-Cal population using the current testing guidelines METHODS: A budget 
impact analysis was constructed from a state Medicaid perspective to depict the 
financial consequences of implementing the testing and linkage to care guide-
lines recommended by the CDC, AASLD and USPSTF for persons born between 
1945 and 1965. The model included disease testing and drug reimbursement cost. 
Of the 2,277,106 Medi-Cal beneficiaries with birthdates between January 1, 1945 
and December 31, 1964, 1,894,144 are in the Fee for Service and not eligible for 
Medicare. Costs of adverse effects and non-adherence were excluded from the 
analysis. RESULTS: The total cost in one budgetary year of testing and treating the 
birth cohort ranged from between $5,230,285,333.21 and $24,207,966,240.39. The cost 
per member per month increases from $0.55 to between $77.76 and $357 if the birth 
cohort testing recommendation is implemented. CONCLUSIONS: In the base case 
analysis, the birth cohort testing increases the overall cost by over 100% from the 
current risk based testing and treating strategy. Furthermore, sensitivity analysis 
shows a 78% increase from the base case estimates if adjustments are made for 
additional risks in the birth cohort. Treatment of genotype 3 has the biggest budget 
impact followed by the treatment of Genotype1 Interferon ineligible persons. This 
research was conducted without the authorization of the California Department of 
Health Care Services and is not endorsed or validated by the Department.
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OBJECTIVES: The objective of the present study was to estimate the financial con-
sequences of using omeprazole immediate-release (IR) oral suspension versus 
intravenous (IV) infusion of pantoprazole for preventing stress-related upper gas-
trointestinal bleeding in critically ill patients from the perspective of the health care 
system. METHODS: An Excel®-based model was developed to compare the cost of 
prevention of upper gastrointestinal bleeding early after intensive care admission using 
the current IV pantoprazole formulation versus omeprazole IR oral suspension. Total 
costs included the cost of acid-suppressive drugs (proton pump inhibitors) and related 
clinical outcomes. Inputs were obtained from a local clinical trial, the Ministry of Health 
database, insurance organizations, hospital and pharmacy registries, the relevant litera-
ture, and expert opinion. The robustness of the input data was investigated by one-way 
sensitivity analysis. During the study period (November 2012 to September 2013), 4,150 
patients were admitted to intensive care units in the different provinces of Iran. The 
model was developed based on the results of a randomized controlled trial in which 
an experimental group and a control group received omeprazole IR oral suspension 
and pantoprazole IV, respectively. RESULTS: According to the proposed model, the cost 
of preventing gastrointestinal bleeding using pantoprazole IV was US$950,000, while 
US$750,000 was spent on omeprazole IR oral suspension. Replacement of IV pantopra-
zole by omeprazole IR oral suspension would lead to an annual cost saving of almost 
US$200,000 (US$4 per member per month) to the health care system. CONCLUSIONS: 
In the present study, a budget impact analysis was performed to assess the financial 
consequences of using omeprazole IR oral suspension in place of pantoprazole IV for 
prevention of upper gastrointestinal bleeding. The better preventive effect of omepra-
zole IR oral suspension when compared with conventional therapy using pantoprazole 
IV was the major reason for the final comparative budgetary savings.
